Black Diamond Therapeutics Reports H1 2026 Financial Results

What Happened

• On August 5, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the six months ended June 30, 2026 and furnished a related press release with the SEC. The press release is included as Exhibit 99.1 to the Current Report on Form 8-K.
• The Form 8-K notes that the furnished information (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other SEC filings unless expressly stated.

Key Details

• Event date: August 5, 2026 (Form 8-K filing reporting results for the six months ended June 30, 2026).
• Press release containing the results: furnished as Exhibit 99.1 to the Form 8-K.
• Reported items on the Form 8-K: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
• Form 8-K signed by Brent Hatzis-Schoch, Chief Operating Officer and General Counsel.

Why It Matters

• This 8-K signals that Black Diamond has released its interim financial results (earnings/financial condition) for H1 2026; investors should read the furnished press release (Exhibit 99.1) for the specific revenue, expense, cash position, and other metrics that drive valuation and trading decisions.
• The filing’s legal note that the release is “furnished” (not “filed”) affects liability and incorporation by reference—meaning full financial and narrative detail may follow in other SEC filings (e.g., Form 10-Q). Review the press release and subsequent SEC filings for complete, actionable financial information.